Gremlin-1 identifies fibrosis and predicts adverse outcome in patients with heart failure undergoing endomyocardial biopsy

Journal of Cardiac Failure

Volumn 19, Issue 10, 2013, Pages 678-684

  Mueller, Karin A L ^a   Tavlaki, Elli ^a   Schneider, Martina ^a   Jorbenadze, Rezo ^a   Geisler, Tobias ^a   Kandolf, Reinhard ^a   Gawaz, Meinrad ^a   Mueller, Iris I ^a   Zuern, Christine S ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Gremlin 1; heart failure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GREMLIN 1 PROTEIN; PROTEIN; TROPONIN I; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC DIAMETER; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; INFLAMMATORY MARKER; MAJOR CLINICAL STUDY; MALE; MARKER GENE; NEW YORK HEART ASSOCIATION CLASS; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SINGLE BLIND PROCEDURE; VIRUS GENOME;

GREMLIN-1, HEART FAILURE;

ADULT; AGED; BIOPSY; ENDOCARDIUM; FEMALE; FIBROSIS; HEART FAILURE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84885912356     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2013.09.001     Document Type: Article

References (36)

1. A. d'Ambrosio, G. Patti, A. Manzoli, G. Sinagra, A. di Lenarda, and F. Silvestri The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review Heart 85 2001 499 504
2. J.L. Jefferies, and J.A. Towbin Dilated cardiomyopathy Lancet 375 2010 752 762
3. B.J. Maron, J.A. Towbin, G. Thiene, C. Antzelevitch, D. Corrado, and D. Arnett Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure, and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention Circulation 113 2006 1807 1816
4. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, E.J. Benjamin, J.D. Berry, and W.B. Borden Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e220
5. D.V. Unverferth, R.D. Magorien, M.L. Moeschberger, P.B. Baker, J.K. Fetters, and C.V. Leier Factors influencing the one-year mortality of dilated cardiomyopathy Am J Cardiol 54 1984 147 152
6. F. Schwarz, G. Mall, H. Zebe, E. Schmitzer, J. Manthey, and H. Scheurlen Determinants of survival in patients with congestive cardiomyopathy: quantitative morphologic findings and left ventricular hemodynamics Circulation 70 1984 923 928
7. J.F. Polak, B.L. Holman, J. Wynne, and W.S. Colucci Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease J Am Coll Cardiol 2 1983 217 224
8. J.R. Wilson, J.S. Schwartz, M.S. Sutton, N. Ferraro, L.N. Horowitz, and N. Reichek Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity J Am Coll Cardiol 2 1983 403 410
9. B.M. Massie, and M. Conway Survival of patients with congestive heart failure: past, present, and future prospects Circulation 75 1987 IV11 IV19
10. S. Cheng, and R.S. Vasan Advances in the epidemiology of heart failure and left ventricular remodeling Circulation 124 2011 e516 e519
11. D.P. Leong, P.L. Madsen, and J.B. Selvanayagam Noninvasive evaluation of myocardial fibrosis: implications for the clinician Heart 96 2010 2016 2024
12. D.R. Hsu, A.N. Economides, X. Wang, P.M. Eimon, and R.M. Harland The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities Mol Cell 1 1998 673 683
13. L.Z. Topol, B. Bardot, Q. Zhang, J. Resau, E. Huillard, and M. Marx Biosynthesis, post-translation modification, and functional characterization of Drm/Gremlin J Biol Chem 275 2000 8785 8793
14. C.C. Rider, and B. Mulloy Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists Biochem J 429 2010 1 12
15. D. Kami, I. Shiojima, H. Makino, K. Matsumoto, Y. Takahashi, and R. Ishii Gremlin enhances the determined path to cardiomyogenesis PLoS One 3 2008 e2407
16. S. Mitola, E. Moroni, C. Ravelli, G. Andres, M. Belleri, and M. Presta Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Drm Blood 112 2008 1154 1157
17. B. Chen, D.G. Blair, S. Plisov, G. Vasiliev, A.O. Perantoni, and Q. Chen Cutting edge: bone morphogenetic protein antagonists Drm/Gremlin and Dan interact with Slits and act as negative regulators of monocyte chemotaxis J Immunol 173 2004 5914 5917
18. S. Mitola, C. Ravelli, E. Moroni, V. Salvi, D. Leali, and K. Ballmer-Hofer Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2 Blood 116 2010 3677 3680
19. S.A. Roxburgh, M. Murphy, C.A. Pollock, and D.P. Brazil Recapitulation of embryological programmes in renal fibrosis - the importance of epithelial cell plasticity and developmental genes Nephron Physiol 103 2006 139 148
20. S. Mezzano, A. Droguett, M.E. Burgos, C. Aros, L. Ardiles, and C. Flores Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis Nephrol Dial Transplant 22 2007 1882 1890
21. K. Koli, M. Myllarniemi, K. Vuorinen, K. Salmenkivi, M.J. Ryynanen, and V.L. Kinnula Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis Am J Pathol 169 2006 61 71
22. W. Boers, S. Aarrass, C. Linthorst, M. Pinzani, R.O. Elferink, and P. Bosma Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins J Biol Chem 281 2006 16289 16295
23. K. Dickstein, A. Cohen-Solal, G. Filippatos, J.J. McMurray, P. Ponikowski, and P.A. Poole-Wilson ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2008 2388 2442
24. H. Mahrholdt, A. Wagner, C.C. Deluigi, E. Kispert, S. Hager, and G. Meinhardt Presentation, patterns of myocardial damage, and clinical course of viral myocarditis Circulation 114 2006 1581 1590
25. L.T. Cooper, K.L. Baughman, A.M. Feldman, A. Frustaci, M. Jessup, and U. Kuhl The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Circulation 116 2007 2216 2233
26. K. Klingel, S. Stephan, M. Sauter, R. Zell, B.M. McManus, and B. Bultmann Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets J Virol 70 1996 8888 8895
27. P. Elliott, B. Andersson, E. Arbustini, Z. Bilinska, F. Cecchi, and P. Charron Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases Eur Heart J 29 2008 270 276
28. P. Seizer, T. Geisler, B. Bigalke, M. Schneider, K. Klingel, and R. Kandolf EMMPRIN and its ligand Cyclophilin A as novel diagnostic markers in inflammatory cardiomyopathy Int J Cardiol 2011
29. C.S. Zuern, K.A. Muller, P. Seizer, T. Geisler, W. Banya, and K. Klingel Cyclophilin A predicts clinical outcome in patients with congestive heart failure undergoing endomyocardial biopsy Eur J Heart Fail 15 2013 176 184
30. A. Frustaci, M. Pieroni, and C. Chimenti The role of endomyocardial biopsy in the diagnosis of cardiomyopathies Ital Heart J 3 2002 348 353
31. C. Kawai From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future Circulation 99 1999 1091 1100
32. S. Rutschow, J. Li, H.P. Schultheiss, and M. Pauschinger Myocardial proteases and matrix remodeling in inflammatory heart disease Cardiovasc Res 69 2006 646 656
33. M. Tanaka, H. Fujiwara, T. Onodera, D.J. Wu, Y. Hamashima, and C. Kawai Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy Br Heart J 55 1986 575 581
34. C.M. Costello, E. Cahill, F. Martin, S. Gaine, and P. McLoughlin Role of gremlin in the lung: development and disease Am J Respiratory Cell and Mol Biol 42 2010 517 523
35. I. Kindermann, M. Kindermann, R. Kandolf, K. Klingel, B. Bultmann, and T. Muller Predictors of outcome in patients with suspected myocarditis Circulation 118 2008 639 648
36. R. Holland, B. Rechel, K. Stepien, I. Harvey, and I. Brooksby Patients' self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death J Card Fail 16 2010 150 156